PAVM
PAVmed Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
PAVmed Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
PAVmed Inc.
2.00
+0.09 · +4.71%
post 1.83 −8.50%
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of PAVmed Inc.'s 2 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of PAVmed Inc.'s 2 closest co-movers, none share that code.
Closest co-movers · 501d
SFBSServisFirst Bancshares×0.09r 0.31MCBMetropolitan Bank Holding×0.08r 0.25Tall tick = annual report · Source: EDGAR
Linked news
Bull2
Bear2
| Manager | Value | % base | |
|---|---|---|---|
| Two Seas Capital | $2.7M | 49.32% | 0.00% |
| First Manhattan | $2.0M | 35.57% | +1298.49% |
| Vanguardindex-like | $365,928 | 6.58% | +941.14% |
| Geodeindex-like | $217,871 | 3.92% | +211.44% |
| Vanguard Fiduciary Trustindex-like | $152,094 | 2.74% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Two Seas Capital | $2.7M | 49.32% | 0.00% |
| First Manhattan | $2.0M | 35.57% | +1298.49% |
| Vanguardindex-like | $365,928 | 6.58% | +941.14% |
| Geodeindex-like | $217,871 | 3.92% | +211.44% |
| Vanguard Fiduciary Trustindex-like | $152,094 | 2.74% | new |
+79.94%
shares held · 10 largest managers